Trial of Cladribine and Low-Dose Cytarabine (LoDAC) Alternating With Decitabine vs. Hypomethylating Agents (HMA) Plus Venetoclax as Frontline Therapy for AML or High-Grade MDS in Patients Unfit for Intensive Induction
University of Florida
University of Florida
Northside Hospital, Inc.
Keros Therapeutics, Inc.
Rush University Medical Center
Samus Therapeutics, Inc.
Baptist Health South Florida
Janssen Research & Development, LLC
Washington University School of Medicine
Yale University
Sensei Biotherapeutics, Inc.
Fred Hutchinson Cancer Center
Kiadis Pharma
City of Hope Medical Center
Jonsson Comprehensive Cancer Center
Immune System Key Ltd
M.D. Anderson Cancer Center
National Institutes of Health Clinical Center (CC)
City of Hope Medical Center
M.D. Anderson Cancer Center
University of Pittsburgh
Jazz Pharmaceuticals
Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Minnesota
Cornerstone Pharmaceuticals
Rutgers, The State University of New Jersey
Mayo Clinic
M.D. Anderson Cancer Center
Mesoblast, Ltd.
Icahn School of Medicine at Mount Sinai
University of California, San Francisco
M.D. Anderson Cancer Center
European Society for Blood and Marrow Transplantation
New Mexico Cancer Research Alliance
University of Cincinnati